E-MTAB-10267
All-trans retinoic reduces the levels of cardiolipins in the NB4 acute promyelocytic leukemia cell-line affecting the autophagy and differentiation responses
All-trans retinoic (ATRA) is used in the treatment of acute promyelocytic  leukemia a rare form of AML characterized by the presence of a specific translocation involving chrosomes 15;17 and causing the production of the PML-RARa fusion protein in 95% of the cases. ATRA differentiates the APL blasts into neutrophilic granulocytes which are short lived cells.  This effect is at the basis of the therapeutic effect of ATRA.
All-trans retinoic (ATRA) is used in the treatment of acute promyelocytic  leukemia a rare form of AML characterized by the presence of a specific translocation involving chrosomes 15;17 and causing the production of the PML-RARa fusion protein in 95% of the cases. ATRA differentiates the APL blasts into neutrophilic granulocytes which are short lived cells.  This effect is at the basis of the therapeutic effect of ATRA.